Are Compounded GLP-1s Going Away? FDA Statement Explained
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
If you have been on a compounded semaglutide or tirzepatide, your inbox, your provider, and probably your group chat have all lit up over the last few weeks. A new FDA statement restating its position on compounded GLP-1s. A fresh round of warning letters sent to telehealth sites in February 2026. New pharmaceutical tariffs on the horizon. An antitrust lawsuit against Eli Lilly and Novo Nordisk. Headlines that say compounded GLP-1s are being "shut down."
We have been getting the same question from readers and customer service messages all week: Is my compounded medication going away? Is the price about to jump? Should I stock up, switch, or panic?
Here is a calm, honest read on what is actually happening, what it means for your prescription, and what we are watching next.
Who This Helps
This post is for anyone currently filling a compounded semaglutide or tirzepatide prescription, anyone thinking about starting one, and anyone who has seen a news alert this week and is not sure whether to worry.
The Short Version
Compounded GLP-1s are not disappearing overnight. The legal pathway that allows patient-specific compounding by state-licensed pharmacies (503A) is still intact. What is happening is a mix of three separate pressures, each moving at its own speed:
- FDA enforcement may be tightening, especially on mass-marketed telehealth compounders and on facilities with quality or labeling problems.
- Pharmaceutical tariffs announced in April 2026 are expected to raise the cost of imported active ingredients once they take effect, which could push some compounded prices up (White House).
- Court cases between compounders and the big brand manufacturers are still in progress, and the outcomes could reshape who is allowed to compound what.
None of these, on their own, make compounded GLP-1s illegal. Together, they might reshape the market - fewer fly-by-night sellers, more scrutiny on quality, and the real possibility of higher prices for some patients.
Pressure One: The FDA Statement on Compounding, and Warning Letters
In September 2025, the FDA issued more than 50 warning letters to companies compounding or manufacturing semaglutide and tirzepatide (Wilson Sonsini analysis). On February 20, 2026 (made public March 3), the agency sent another batch of 30 letters, this time focused heavily on telehealth sites marketing compounded GLP-1s (Fierce Pharma coverage, Spencer Fane legal breakdown). The FDA's own statement on unapproved GLP-1 drugs used for weight loss is available directly from the agency.
The letters mostly target two things:
FDA-approved
- False or misleading marketing, including claims that compounded products are "generic versions" or contain the "same active ingredient" as FDA-approved brands.
- Quality and sterility concerns at specific compounding facilities. Part of routine inspections and investigations for the FDA.
- Marketing with “the same active ingredient” as FDA-approved medications. Compounded medications are not FDA-approved and the FDA does not want confusion for consumers around what they’re getting. Misleading marketing that makes it unclear that compounded medication is different from FDA-approved medications has been called out.
The most recent FDA statement also leaned hard on what counts as "customization." Most of the conditions it listed are already in the Food, Drug, and Cosmetic Act, but the agency specifically pushed back on the idea that adding something like B12 to semaglutide qualifies as a customized, patient-specific compound (see AJMC's reporting on the FDA restricting ingredients in mass-marketed compounded GLP-1s and Sabina’s substack writing). That matters because "customization" is the doorway 503A pharmacies walk through to compound a GLP-1 at all. If the FDA narrows what counts as a real customization, the doorway gets smaller. Worth noting: that statement landed the same day Eli Lilly received FDA approval for Foundayo, its oral GLP-1, which made the timing feel less coincidental to a lot of people in the industry.
The statement also reminded 503B outsourcing facilities of the existing Food, Drug, and Cosmetic Act limits on compounding drugs that are essentially copies of FDA-approved products. It isn't a new rule so much as a reminder of rules that were already on the books, but the volume matters.
A few important nuances people keep missing in the headlines:
- The FDA is not banning compounded semaglutide or tirzepatide across the board.
- 503A compounding (patient-specific prescriptions filled by state-licensed pharmacies) is still legal and still happening.
If your medication comes from a reputable 503A pharmacy working with a licensed prescriber who evaluated you personally, the April 1st FDA statement should not impact your access. That said, this is a good moment to confirm with your provider which pharmacy is filling your prescription.
Separately from the April 1 statement, it's still worth confirming with your provider which pharmacy is filling your prescription and whether that pharmacy has received any recent FDA warning letters — those actions have been ongoing throughout 2025 and 2026 and are a better signal of pharmacy quality than any single announcement.
For background on what a real recall looks like and how to read one, our earlier post Semaglutide & Tirzepatide Recall: What to Know walks through the ProRx recall from late 2025 and what the FDA language actually signals.
Pressure Two: Pharmaceutical Tariffs
This is the one most people have not connected yet.
A new tariff policy announced in April 2026 will add a 100% ad valorem duty on imports of certain patented pharmaceuticals and associated pharmaceutical ingredients, with a reduced 20% rate for companies with approved plans to move production to the United States. Under the April 2026 White House fact sheet, the tariffs come into effect 120 days after the announcement for certain large companies and 180 days for smaller companies, meaning the real cost impact is still ahead of us, not behind us.
Generic pharmaceuticals and their ingredients are not currently subject to these Section 232 tariffs. You can read the policy directly in the White House executive action on adjusting pharmaceutical imports, and the National Association of Chain Drug Stores (NACDS) tariff impact update breaks down what it means for pharmacies.
Here is why that matters for compounded GLP-1s: many compounding pharmacies source their active pharmaceutical ingredient (or API, which is the actual semaglutide or tirzepatide powder) from overseas suppliers in China, India, and Europe. When import costs on those ingredients rise, pharmacies either absorb the cost or pass it along. Paloma Health's analysis on how drug tariffs could drive up the cost of thyroid, HRT, and GLP-1 medications walks through the supplier landscape and why patients paying out of pocket are most exposed.
What this looks like in practice is that some pharmacies may absorb the cost. Others might lock in inventory at pre-tariff pricing, which can create short-term stability, but may raise prices later.
If you want to understand why your monthly cost might move even if nothing about your dose or pharmacy changes, the tariff line item is the quietest reason and probably the most durable one.
For the broader cost picture across brand, compounded, and oral options, our post GLP-1 Cost Breakdown is a useful companion read.
Why Brand GLP-1s May Dodge the Tariff Hit
Separately, Eli Lilly and Novo Nordisk have negotiated Most Favored Nation deals with the Trump administration that include a three-year tariff exemption in exchange for lower GLP-1 prices through TrumpRx and expanded Medicare/Medicaid access. That shields the brand drugs from the new tariffs, but does nothing for compounders sourcing API independently (Pharmacy Times on the Lilly/Novo MFN deals, Fierce Pharma). That said, pricing will not be better on TrumpRx, and our medication-specific price calculators linked in the next paragraph will be your best resource for finding deals.
That means the pricing pressure from tariffs is likely to be felt most acutely on the compounded side of the market, while Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo keep their negotiated pricing intact through TrumpRx. If you're weighing compounded vs. brand on cost alone, that asymmetry is worth knowing about (Pharmacy Times, CNBC, AJMC).
Pressure Three: The Court Cases
This is the part that gets the most headlines. It's also the part least likely to change anything in the short term.
On January 14, 2026, Strive Compounding Pharmacy filed an antitrust lawsuit in the US District Court for the Western District of Texas against Eli Lilly and Novo Nordisk. The complaint alleges that the two manufacturers entered into exclusive agreements with telehealth companies that prohibited those platforms from working with compounding pharmacies - effectively cutting off patient access to personalized compounded GLP-1s. You can read the official Strive press release on PRNewswire, BioSpace's reporting on the alleged coordinated crackdown, and the actual complaint filed in the Western District of Texas.
That case is still active. No final ruling yet.
The Empower case isn't a one-off. Eli Lilly and Novo Nordisk have filed hundreds of lawsuits and cease-and-desist actions against compounding pharmacies and telehealth platforms over the past year, with Lilly's 2025 suit against Empower Clinic Services — a 503A compounding pharmacy and 503B outsourcing facility — as one of the more-cited examples. Lilly accused Empower of 'unlawfully manufacturing and selling untested, unapproved weight loss drugs on a large scale’ (Harris Beach law firm summary, Buchanan Ingersoll & Rooney's GLP-1 litigation update).
Where this lands depends on the courts. A ruling in favor of compounders could protect patient-specific access and clip exclusive telehealth-brand deals. A ruling in favor of the brands could further restrict which compounded versions are allowed and for whom.
If you want to understand why the supply-and-legality picture keeps shifting, our explainer GLP-1s vs Peptides: What They Really Mean covers the difference between an FDA-approved GLP-1 medication and the research-peptide and compounded worlds that sit next to it.
The Hidden Cost of Ambiguity: Why "Maybe" Hurts the Good Pharmacies
There is a quieter story underneath the headlines, and it is the one our founder Sabina has been talking about on TikTok and YouTube this week. It is worth pulling forward, because it explains a pattern most patients never see.
The shortage officially ended more than a year ago, but the questions it kicked off have not. Is compounding going away? Is the FDA going to enforce anything? When the rules stay ambiguous, the pharmacies that get hurt most aren't the sketchy ones — they're the careful ones.
Highly compliant compounding pharmacies, including family-run operations that have been around for decades, look at the legal risk and the unclear enforcement and decide it is beyond their risk tolerance. Some of them have simply chosen not to touch GLP-1s at all. Others have stepped out of the GLP-1 space temporarily, watched nothing happen, and stepped back in months later when it became clear enforcement was not arriving.
The pharmacies that do not flinch during these announcements tend to be the ones that were built specifically to ride the GLP-1 wave. They are often less concerned with regulatory compliance, more willing to shut down if the FDA or a state board of pharmacy actually forces the issue, and not particularly interested in the long, careful work of staying clean. When the cautious pharmacies step out and the opportunistic ones stay in, the market quietly tilts toward the players with the lowest standards.
That is the real cost of ambiguity. It is not just confusing for patients. It rewards the wrong kind of pharmacy and pushes the right kind out. A clearer enforcement pathway - even a stricter one – would actually be better for patient safety than the current limbo, because it would let the careful, safety-oriented pharmacies plan, comply, and keep serving patients without feeling like they are gambling their entire business every quarter.
If you want to know whether your pharmacy is one of the careful ones, the question to ask is not "are you legal" - almost everyone will say yes. The better questions are: How long have you been compounding (not just GLP-1s, but anything)? Where do you source your API, and do you only use sources on the FDA’s greenlist? A pharmacy that can answer those calmly is usually the kind you want.
So, Are Compounded GLP-1s Going Away?
Short answer: no, not as a category.
Longer answer: the mass-marketed, "order it like a supplement" version of compounded GLP-1s is under real pressure. Patient-specific 503A compounding, filled by a licensed pharmacy under the direction of a provider who has actually evaluated you, is still legal and is expected to remain so in the near term.
What is likely to change:
- More telehealth brands, not fewer, entering the compounded GLP-1 space over the next year as the regulatory picture clarifies and the remaining players compete on quality and transparency.
- A slow legal timeline — most of the headline-grabbing cases (Strive, Empower, and related filings) will take one to two years to resolve even if dismissed quickly, so don't expect a single court ruling to change your pharmacy access this year.
- More 503B outsourcing facilities entering the GLP-1 space, not fewer, as the April 1 statement's bark turns out to be louder than its bite and careful operators see an opening.
Will My Price Go Up?
Possibly. The honest answer is that it depends on where your pharmacy sources its API, whether they have pre-tariff inventory, and whether they are absorbing costs or passing them on.
A few things worth doing right now:
- Ask your pharmacy (or the telehealth provider who handles your pharmacy relationship) whether they anticipate price changes in the next 60 to 90 days.
- Ask whether the pharmacy filling your prescription has received any FDA warning letters in the last year.
- If you have a savings or intro-price offer from a brand manufacturer, read the fine print. Manufacturer savings cards and intro pricing often expire after a set number of refills, and the post-intro cash price can be significantly higher. This is true on both the brand side and the compounded side - an advertised monthly rate is not always the rate you will be paying six months in.
Whatever shifts in the next few months (prices, pharmacy availability, or which brands are in the conversation), GLP Winner will keep tracking it in real time. Our job is to help you navigate the changes as they happen, not to hand you a warning and walk away.
Should I Stock Up?
We get this question a lot, and the answer is almost always no.
Compounded GLP-1s have shorter Beyond-Use Dates than FDA-approved products - often 30 to 90 days after dispensing, depending on the pharmacy, state, and the formulation. Buying a pile of vials you cannot safely use is not a hedge; it is expensive waste. If you are worried about continuity, the better move is to have an honest conversation with your provider about what your backup path looks like before you need it.
Our earlier post What To Do With Extra GLP-1 in a Vial has more on how to think about storage, Beyond-Use Dates, and the difference between "I have a little extra" and "I am trying to stockpile."
FDA Approval vs. Insurance Coverage (Again)
This comes up every time a compounded-versus-brand question shows up. Even when a medication is FDA-approved, your insurance might not cover it for your specific diagnosis, or might only cover it with prior authorization and step therapy. A prescription is not the same as coverage. Compounded and FDA-approved GLP-1s are not generic-and-brand versions of the same treatment. They are distinct treatment paths with different ingredients, legal standing, cost structures, and clinical use cases. If you’re weighing a change, think of it as switching treatments, not swapping products.
If you do have insurance coverage and a qualifying health condition but are running into prior authorization walls, you do not have to navigate that alone. Our GLP Winner comparison tool matches you with providers who are experienced at handling prior authorizations and appeals, so you can find someone who will actually do the paperwork fight alongside you instead of handing you a denial letter and wishing you luck.
What GLP Winner Is Watching
We are tracking a few specific things over the next several weeks:
- Any new FDA warning letters or enforcement actions on specific compounding facilities.
- Court movement in the Strive antitrust case, Empower litigation, and other lawsuits in the space.
- Announced price changes from the larger compounding pharmacies or providers.
- Updates from 503B outsourcing facilities, which face more federal oversight than 503A pharmacies and are often the first to move on pricing and availability.
When any of those move, we will update this post and link it in future insights so you are not hunting for the latest version.
Who Should Talk to Their Provider This Month
If you are currently on a compounded GLP-1, this is a reasonable moment - not a panic moment - to check in with your prescriber.
Compounded GLP-1s are prescription medications, which means the decisions about them belong in the room with your provider, not in a comment section. If you do not currently have a provider guiding your GLP-1 care, that is the first thing to fix.
Final Takeaway
Compounded GLP-1s are not disappearing, but the ground under them is shifting. The FDA has restated its position on customization. Tariffs may push prices up on imported ingredients once they take effect, depending on how the administration and FDA actually implement them. For some patients, nothing needs to change this week. For others (especially anyone whose pharmacy has been named in a warning letter or flagged for sourcing issues) it may mean acting sooner rather than later.
The best thing you can do is know where your medication comes from, know what you would do if the price or the supply changed, and keep your provider in the loop.
If you enjoy posts like these, subscribe to the GLP Winner newsletter for more.
Sources
Keep Reading
FDA recalls compounded semaglutide and tirzepatide by ProRx LLC for sterility concerns. See if your vial’s affected and what to do next.
Not all peptides are GLP-1s. Learn the difference between FDA-approved GLP-1s, pharmacy-compounded, grey market, and wellness peptides.
Unsure about small ‘extra’ in your GLP-1 vial? Learn what’s normal, what’s safe, and when to call your provider — based on FDA and clinical guidance.
Curated by
